RLAY

Relay Therapeutics, Inc. [RLAY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

RLAY Stock Summary

Top 10 Correlated ETFs

RLAY


Top 10 Correlated Stocks

RLAY


In the News

12:39 28 Mar 2024 RLAY

3 Precision Medicine Stocks That Could Benefit From the Industry's Rise

Now might be a great time for investors to consider investing in precision medicine stocks. For those who don't know, precision medicine is an approach to disease treatment and prevention that tailors medical decisions to the individual patient.

10:56 28 Mar 2024 RLAY

Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?

The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

04:05 28 Mar 2024 RLAY

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: TD Cowen's 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 a.m.

10:56 28 Mar 2024 RLAY

Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?

The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 131.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

04:05 28 Mar 2024 RLAY

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024.

04:31 28 Mar 2024 RLAY

Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

02:57 28 Mar 2024 RLAY

The 7 Best Penny Stocks for 200% Returns

This year is going to offer a lot of opportunities for risk seeking investors. The world of penny stocks is well known to be speculative and is usually the domain of investors possessing a risk seeking profile.

04:05 28 Mar 2024 RLAY

Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D.

07:11 28 Mar 2024 RLAY

AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence

We're still in the initial stages of a massively disruptive artificial intelligence ( AI ) boom. Big Tech is investing billions of dollars into it.

02:05 28 Mar 2024 RLAY

Relay Therapeutics: Market Is Underestimating Lirafugratinib's Potential (Rating Upgrade)

Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ample short-term liquidity and significant assets covering debts. Market sentiment is skeptical, with high short interest and the stock's underperformance relative to the S&P 500, but prominent institutions show confidence in the company's long-term prospects.

RLAY Financial details

Company Rating
Sell
Market Cap
1.02B
Income
-335.04M
Revenue
25.55M
Book val./share
0.01
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
323
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-4.92
Forward P/E
-2.74
PEG
5.6
P/S
56.71
P/B
1.86
P/C
816
P/FCF
-5.33
Quick Ratio
15.98
Current Ratio
16.39
Debt / Equity
0.07
LT Debt / Equity
0.06
-
-
EPS (TTM)
-2.07
EPS next Y
-2.98
EPS next Q
-0.72
EPS this Y
-99.88%
EPS next Y
43.93%
EPS next 5Y
24.96%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-100%
EPS Q/Q
-99.87%
-
-
-
-
SMA20
-24.54%
SMA50
-31.31%
SMA100
20.9%
Inst Own
55.64%
Inst Trans
0.53%
ROA
-33%
ROE
-34%
ROC
-0.41%
Gross Margin
100%
Oper. Margin
-1371%
Profit Margin
-1143%
Payout
-
Shs Outstand
131.18M
Shs Float
92.2M
-
-
-
-
Target Price
22.83
52W Range
5.95-19.23
52W High
-57.05%
52W Low
+63.2%
RSI
41.12
Rel Volume
0.96
Avg Volume
1.07M
Volume
1.03M
Perf Week
8.8%
Perf Month
-9.23%
Perf Quarter
-5.01%
Perf Half Y
-2.97%
-
-
-
-
Beta
1.662
-
-
Volatility
0.22%, 1.14%
Prev Close
7.79%
Price
8.16
Change
7.37%

RLAY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
01.940.030.010
Net income per share
-15.53-1.15-5.22-2.270
Operating cash flow per share
-15.45-2.4-0.78-2.040
Free cash flow per share
-17.32-2.45-0.82-2.130
Cash per share
83.1115.9117.216.450.01
Book value per share
-42.1517.919.448.470.01
Tangible book value per share
-42.1517.919.418.450.01
Share holders equity per share
-42.1517.919.448.470.01
Interest debt per share
5.80.570.240.440
Market cap
150.05M1.77B2.92B1.68B1349.57B
Enterprise value
132.93M1.35B1.99B735.6M1349.48B
P/E ratio
-2.26-36.14-5.88-6.59-3.95K
Price to sales ratio
021.43964.561.21K52.83K
POCF ratio
-2.27-17.28-39.27-7.31-4.49K
PFCF ratio
-2.02-16.96-37.52-7.03-4.43K
P/B Ratio
-0.832.323.251.761.79K
PTB ratio
-0.832.323.251.761.79K
EV to sales
016.31655.82532.6552.83K
Enterprise value over EBITDA
-1.64-25.8-22.24-2.28-3.55K
EV to operating cash flow
-2.01-13.15-26.7-3.21-4.49K
EV to free cash flow
-1.79-12.91-25.51-3.08-4.43K
Earnings yield
-0.44-0.03-0.17-0.150
Free cash flow yield
-0.49-0.06-0.03-0.140
Debt to equity
-0.140.030.030.060.07
Debt to assets
0.060.030.020.050.06
Net debt to EBITDA
0.218.110.472.920.24
Current ratio
30.0856.4940.141625.44
Interest coverage
00034.140
Income quality
0.881.960.20.790.88
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00.4718.9547.782.93
Research and developement to revenue
01.2157178.3912.92
Intangibles to total assets
00000
Capex to operating cash flow
0.120.020.050.040.01
Capex to revenue
0-0.02-1.15-6.56-0.16
Capex to depreciation
-2.81-0.54-0.88-2.19-0.78
Stock based compensation to revenue
00.391640.653.37
Graham number
121.3721.5333.320.770.02
ROIC
0.57-0.06-0.53-0.25-0.39
Return on tangible assets
-0.17-0.06-0.49-0.23-0.41
Graham Net
-50.8513.7112.4915.20.01
Working capital
348.55M756.47M951.92M955.8M739.83M
Tangible asset value
-180.44M763.29M895.51M947.92M749.7M
Net current asset value
-212.97M733.56M865.61M869.95M678.13M
Invested capital
-0.140.030.030.060.07
Average receivables
041.33M43.8M5.08M2.61M
Average payables
5.85M6.67M7.31M9.43M9.89M
Average inventory
0-119.03M-460.28M-335.19M6.06M
Days sales outstanding
0365595.281.38K0
Days payables outstanding
896.91653.17769.62934.86638.07
Days of inventory on hand
0-24.48K-63.47K1.07K0
Receivables turnover
010.610.260
Payables turnover
0.410.560.470.390.57
Inventory turnover
0-0.01-0.010.340
ROE
0.37-0.06-0.55-0.27-0.45
Capex per share
-1.87-0.05-0.04-0.080

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.210
Net income per share
-0.36-0.72-0.81-0.540
Operating cash flow per share
-0.47-0.55-0.56-0.620
Free cash flow per share
-0.49-0.57-0.58-0.620
Cash per share
15.267.737.166.630.01
Book value per share
7.867.286.666.370.01
Tangible book value per share
7.847.266.646.350.01
Share holders equity per share
7.867.286.666.370.01
Interest debt per share
0.450.410.460.450
Market cap
1.81B2B1.53B1.03B1349.57B
Enterprise value
866.07M1.89B1.44B931.24M1349.48B
P/E ratio
-10.43-5.72-3.88-3.91-4.04K
Price to sales ratio
7.14K8.84K12.84K40.79-1.35B
POCF ratio
-31.66-29.77-22.28-13.63-15.13K
PFCF ratio
-30.43-28.94-21.8-13.53-15.11K
P/B Ratio
1.92.261.891.321.79K
PTB ratio
1.92.261.891.321.79K
EV to sales
3.42K8.38K12.09K36.95-1.35B
Enterprise value over EBITDA
-9.22-18.72-13.19-12.66-14.21K
EV to operating cash flow
-15.17-28.21-20.96-12.35-15.13K
EV to free cash flow
-14.58-27.43-20.51-12.26-15.11K
Earnings yield
-0.02-0.04-0.06-0.060
Free cash flow yield
-0.03-0.03-0.05-0.070
Debt to equity
0.060.060.070.070.07
Debt to assets
0.050.050.060.060.06
Net debt to EBITDA
10.021.030.831.310.95
Current ratio
1613.612.3616.3925.44
Interest coverage
21.3414.5800-13.29
Income quality
0.850.710.71.151.07
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
64.7186.63169.080.73-16.77K
Research and developement to revenue
265.92366.49741.183.23-77.5K
Intangibles to total assets
00000
Capex to operating cash flow
0.040.030.020.010
Capex to revenue
-9.15-8.47-12.63-0.02118
Capex to depreciation
-1.99-1.6-1.13-0.43-0.09
Stock based compensation to revenue
54.6195.21196.730.87-19.27K
Graham number
7.9610.8611.018.780.01
ROIC
-0.04-0.09-0.1-0.08-0.13
Return on tangible assets
-0.04-0.08-0.1-0.07-0.1
Graham Net
14.116.545.955.650.01
Working capital
955.8M887.92M812.77M781.05M739.83M
Tangible asset value
947.92M881.11M807.82M776.07M749.7M
Net current asset value
869.95M804.24M732.45M703.21M678.13M
Invested capital
0.060.060.070.070.07
Average receivables
5.17M5.23M2.65M144.5K105.5K
Average payables
10.03M11.21M13.31M14.07M11.28M
Average inventory
14.46M11.69M10.29M13.3M8.65M
Days sales outstanding
1.86K2.08K58.990.750
Days payables outstanding
816.48889.77997.02881.71602.9
Days of inventory on hand
934.73847.22627.841.14K0
Receivables turnover
0.050.041.53119.440
Payables turnover
0.110.10.090.10.15
Inventory turnover
0.10.110.140.080
ROE
-0.05-0.1-0.12-0.08-0.11
Capex per share
-0.02-0.02-0.0100

RLAY Frequently Asked Questions

What is Relay Therapeutics, Inc. stock symbol ?

Relay Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol RLAY

Is Relay Therapeutics, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $22.83. The lowest prediction is $12.5 and the highest is $33

What is RLAY stock prediction ?

What is Relay Therapeutics, Inc. stock quote today ?

Relay Therapeutics, Inc. stock price is $8.16 today.

Is Relay Therapeutics, Inc. stock public?

Yes, Relay Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap